Format

Send to

Choose Destination
See comment in PubMed Commons below
Toxins (Basel). 2010 Dec;2(12):2795-815. doi: 10.3390/toxins2122795. Epub 2010 Dec 3.

Targeted secretion inhibitors-innovative protein therapeutics.

Author information

1
Syntaxin Ltd, Units 4-10 The Quadrant, Barton Lane, Abingdon, OXON, OX14 3YS, UK. keith.foster@syntaxin.com

Abstract

Botulinum neurotoxins are highly effective therapeutic products. Their therapeutic success results from highly specific and potent inhibition of neurotransmitter release with a duration of action measured in months. These same properties, however, make the botulinum neurotoxins the most potent acute lethal toxins known. Their toxicity and restricted target cell activity severely limits their clinical utility. Understanding the structure-function relationship of the neurotoxins has enabled the development of recombinant proteins selectively incorporating specific aspects of their pharmacology. The resulting proteins are not neurotoxins, but a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSI), suitable for the treatment of a wide range of diseases where secretion plays a major role. TSI proteins inhibit secretion for a prolonged period following a single application, making them particularly suited to the treatment of chronic diseases. A TSI for the treatment of chronic pain is in clinical development.

KEYWORDS:

SNARE proteins; biologics; botulinum neurotoxins; genetic engineering; protein therapeutics; recombinant proteins

PMID:
22069575
PMCID:
PMC3153183
DOI:
10.3390/toxins2122795
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Support Center